Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
Description for laymen
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)
JSON Data
{
"short_title": "eVOLVE-Lung02",
"data_mode": "900",
"data_mode_number": "000002373",
"official_title": "A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, \r\nOpen-Label, Global Study to Determine the Efficacy of \r\nVolrustomig (MEDI5752) Plus Chemotherapy Versus \r\nPembrolizumab Plus Chemotherapy for First-Line Treatment of \r\nPatients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) \r\n(eVOLVE-Lung02) ",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": "NCT05984277",
"eudract_number": "2023-000056-38",
"general_contact_email": null,
"general_contact_phone": null,
"hauptpruefer_dd_name": "Dr. med. Felix Saalfeld",
"description_laie_de": "Eine zweiarmige, parallele, randomisierte, multizentrische Phase-III-Studie, offene, globale Studie zur Bestimmung der Wirksamkeit von Volrustomig (MEDI5752) plus Chemotherapie im Vergleich zu Pembrolizumab plus Chemotherapie f\u00fcr die Erstbehandlung von Patienten mit metastasiertem nicht-kleinzelligem Lungenkrebs (mNSCLC)",
"description_laie_en": "A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)",
"description_expert_de": "Eine zweiarmige, parallele, randomisierte, multizentrische Phase-III-Studie, offene, globale Studie zur Bestimmung der Wirksamkeit von Volrustomig (MEDI5752) plus Chemotherapie im Vergleich zu Pembrolizumab plus Chemotherapie f\u00fcr die Erstbehandlung von Patienten mit metastasiertem nicht-kleinzelligem Lungenkrebs (mNSCLC)",
"description_expert_en": "A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 10,
"sub_cat_id": 50
}
